Elcin: Elacestrant U Er+/Her2- Metastatskom Raku Dojke Koji Prethodno Nije Bio Liječen Inhibitorom Cdk4/6

ELCIN: elacestrant in CDK4/6 inhibitor-naïve ER+/HER2- metastatic breast cancer

Elacestrant in ER+/HER2- mBC: Overview of the EMERALD subgroup analysis

COR2ED The Heart of Medical Education

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy pts

Unmet needs in the use of CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer

ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancer

Assessing elacestrant in ctDNA-positive patients with ER+ breast cancer

Case 2: CDK4/6 Inhibitor Recommendations in ER+ Breast Cancer

Targeted Oncology

EMERALD: elacestrant vs physicians choice in ER+/HER2- breast cancer

ER+ metastatic breast cancer: Elacestrant and beyond

COR2ED The Heart of Medical Education

EMERALD: elacestrant vs. SOC for patients with ER+ HER2- metastatic breast cancer

TREAT ctDNA: early elacestrant intervention for ER+/HER2- breast cancer

Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metas...

ER+/HER2+ Metastatic Breast Cancer

How is HER2 positive breast cancer treated? #shorts

What does the future hold for SERDs in ER+ breast cancer?

First-line camizestrant for ER+/HER2- advanced breast cancer

ELECTRA: novel combinations for HR-positive breast cancer with CNS metastases

New Breast Cancer Clinical Trial: Imlunestrant for Breast Neoplasms

Power Life Sciences

AMEERA-3: SERD for ER+ HER2- breast cancer

Case 2: ER+ Breast Cancer

Targeted Oncology